Open AccessAssessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center
Author(s) -
Sudha Murthy,
DG Sandhya,
Faiq Ahmed,
KIravathy Goud,
Monal Dayal,
Kundoly Velayudhan Suseela,
SenthilJ Rajappa
Publication year - 2011
Publication title -
indian journal of pathology and microbiology/indian journal of pathology and microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.217
H-Index - 31
eISSN - 0974-5130
pISSN - 0377-4929
DOI - 10.4103/0377-4929.85087
Subject(s) - polysomy , fluorescence in situ hybridization , immunohistochemistry , breast cancer , concordance , trastuzumab , medicine , oncology , pathology , cancer , chromosome 17 (human) , biology , chromosome , gene , genetics
HER-2/neu status determines the eligibility for targeted therapy with trastuzumab in breast carcinoma. Evaluation for HER-2/neu protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) has become the gold standard.